ado-trastuzumab emtansine + tucatinib

Ado-trastuzumab emtansine + tucatinib is a combination therapy consisting of two targeted agents used in the treatment of HER2-positive breast cancer, particularly in patients with unresectable locally advanced or metastatic disease. Ado-trastuzumab emtansine (T-DM1, brand name Kadcyla) is an antibody-drug conjugate composed of the monoclonal antibody trastuzumab linked to the cytotoxic agent DM1 (emtansine). Trastuzumab binds to the extracellular domain IV of HER2 (ERBB2), inhibiting receptor signaling and mediating antibody-dependent cellular cytotoxicity; after internalization, DM1 disrupts microtubule function leading to cell cycle arrest and apoptosis[9]. Tucatinib (brand name Tukysa) is a highly selective small molecule tyrosine kinase inhibitor that targets the intracellular kinase domain of HER2, suppressing phosphorylation and downstream signaling through AKT and MAPK pathways[6][8]. The combination leverages complementary mechanisms—extracellular inhibition by trastuzumab/DM1 and intracellular blockade by tucatinib—to enhance anti-tumor activity. This regimen has shown improved progression-free survival compared to T-DM1 alone in clinical trials for previously treated HER2-positive metastatic breast cancer[3][5][7].

Brand names

Kadcyla + Tukysa

Other names

ado-trastuzumab emtansine plus tucatinibT-DM1 plus tucatinibT-DM-1 plus tucatinibT-DM 1 plus tucatinib